Matthew S. Block

4.8k total citations
142 papers, 2.3k citations indexed

About

Matthew S. Block is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Matthew S. Block has authored 142 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 70 papers in Oncology, 51 papers in Immunology and 42 papers in Molecular Biology. Recurrent topics in Matthew S. Block's work include Immunotherapy and Immune Responses (41 papers), Cancer Immunotherapy and Biomarkers (33 papers) and CAR-T cell therapy research (30 papers). Matthew S. Block is often cited by papers focused on Immunotherapy and Immune Responses (41 papers), Cancer Immunotherapy and Biomarkers (33 papers) and CAR-T cell therapy research (30 papers). Matthew S. Block collaborates with scholars based in United States, Canada and Italy. Matthew S. Block's co-authors include Svetomir N. Markovic, Ribhu K. Kaul, Kimberly R. Kalli, Keith L. Knutson, Candace L. Haddox, Anupam Kotwal, Matthew P. A. Fisher, Lisa A. Kottschade, D. N. Sheng and Olexei I. Motrunich and has published in prestigious journals such as Nature, Physical Review Letters and Journal of Clinical Oncology.

In The Last Decade

Matthew S. Block

134 papers receiving 2.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Matthew S. Block United States	27	992	707	563	258	233	142	2.3k
Yoïchi Tanaka Japan	35	992 1.0×	446 0.6×	1.1k 1.9×	265 1.0×	265 1.1×	199	4.2k
Takashi Okamura Japan	37	952 1.0×	1.1k 1.5×	1.4k 2.5×	398 1.5×	39 0.2×	294	6.1k
Steven A. Spencer Australia	22	474 0.5×	854 1.2×	1.9k 3.3×	667 2.6×	56 0.2×	31	5.2k
Gad Singer Switzerland	28	900 0.9×	614 0.9×	1.0k 1.8×	210 0.8×	32 0.1×	106	3.7k
Lachlan Whitehead Australia	28	397 0.4×	733 1.0×	1.2k 2.2×	164 0.6×	56 0.2×	66	2.8k
S. Iwata Japan	39	515 0.5×	1.7k 2.4×	794 1.4×	156 0.6×	232 1.0×	230	4.7k
Yukio Kondo Japan	24	676 0.7×	592 0.8×	512 0.9×	155 0.6×	34 0.1×	72	2.1k
Jaegil Kim United States	26	562 0.6×	190 0.3×	1.9k 3.3×	531 2.1×	175 0.8×	67	3.3k
Fabrizio Zanconati Italy	34	712 0.7×	286 0.4×	865 1.5×	134 0.5×	37 0.2×	183	3.6k
Chunying Song Canada	28	782 0.8×	380 0.5×	1.7k 3.0×	69 0.3×	115 0.5×	105	3.4k

Countries citing papers authored by Matthew S. Block

Since Specialization

Citations

This map shows the geographic impact of Matthew S. Block's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew S. Block with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew S. Block more than expected).

Fields of papers citing papers by Matthew S. Block

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew S. Block. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew S. Block. The network helps show where Matthew S. Block may publish in the future.

Co-authorship network of co-authors of Matthew S. Block

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew S. Block. A scholar is included among the top collaborators of Matthew S. Block based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew S. Block. Matthew S. Block is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Punekar, Salman R., J. Randolph Hecht, Diane M. Simeone, et al.. (2024). EVEREST-2: A seamless phase 1/2 study of A2B694, a mesothelin (MSLN) logic-gated Tmod CAR T-cell therapy, in patients with solid tumors that show MSLN expression and human leukocyte antigen (HLA)-A*02 loss of heterozygosity (LOH).. Journal of Clinical Oncology. 42(16_suppl). TPS2699–TPS2699. 5 indexed citations

Hendrickson, Andrea E. Wahner, Nathan R. Foster, Matthew S. Block, et al.. (2024). Phase II clinical trial of PLX038 in patients with platinum resistant ovarian, primary peritoneal and fallopian tube cancer.. Journal of Clinical Oncology. 42(16_suppl). TPS5630–TPS5630. 1 indexed citations

Venkateswaran, Sriram, Antonio Santo, Eli Silvert, et al.. (2024). Identification and Characterization of Immune Checkpoint Inhibitor–Induced Toxicities From Electronic Health Records Using Natural Language Processing. JCO Clinical Cancer Informatics. 8(8). e2300151–e2300151. 6 indexed citations

Santos, João M., Matthew S. Block, Johanna Mäenpää, et al.. (2024). PROTA: A phase I clinical trial combining an oncolytic adenovirus encoding for TNFa and IL-2 with pembrolizumab for the treatment of platinum-resistant or -refractory ovarian cancer.. Journal of Clinical Oncology. 42(16_suppl). 5562–5562.

Hieken, Tina J., Shahneen Sandhu, Zeynep Eroglu, et al.. (2024). LBA41 Long-term survival with neoadjuvant therapy in melanoma: Updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Annals of Oncology. 35. S1232–S1232. 8 indexed citations

Kottschade, Lisa A., Gregory R. Pond, Anthony J. Olszanski, et al.. (2023). SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma. Clinical Cancer Research. 29(12). 2220–2225. 7 indexed citations

Smith, Katherine E., Sarah M. Jenkins, Anastasios Dimou, et al.. (2023). Immune infiltrates in metastatic uveal melanoma liver metastases and associations with clinical outcomes.. Journal of Clinical Oncology. 41(16_suppl). 9538–9538. 1 indexed citations

Massey, Shane, Michael J. Hansen, Courtney L. Erskine, et al.. (2022). Comparison of replicating and nonreplicating vaccines against SARS-CoV-2. Science Advances. 8(34). eabm8563–eabm8563. 9 indexed citations

Multinu, Francesco, Simone Garzon, Amy L. Weaver, et al.. (2021). Adjuvant chemotherapy in early-stage endometrioid endometrial cancer with >50% myometrial invasion and negative lymph nodes. International Journal of Gynecological Cancer. 31(4). 537–544. 3 indexed citations

10.

Narasimhulu, Deepa Maheswari, Matthew S. Block, Amy L. Weaver, et al.. (2021). Sequencing chemotherapy before radiotherapy for women with stage IIIC endometrial cancer. International Journal of Gynecological Cancer. 31(5). 702–708. 3 indexed citations

11.

Hieken, Tina J., Amy E. Glasgow, Elizabeth Ann L. Enninga, et al.. (2020). Sex-Based Differences in Melanoma Survival in a Contemporary Patient Cohort. Journal of Women s Health. 29(9). 1160–1167. 23 indexed citations

12.

Somaiah, Neeta, Matthew S. Block, Joseph W. Kim, et al.. (2019). First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1. Clinical Cancer Research. 25(19). 5808–5817. 71 indexed citations

13.

Wang, Lei, Sara J. Felts, Virginia P. Van Keulen, et al.. (2018). Integrative Genome-Wide Analysis of Long Noncoding RNAs in Diverse Immune Cell Types of Melanoma Patients. Cancer Research. 78(15). 4411–4423. 24 indexed citations

14.

Kalli, Kimberly R., Matthew S. Block, Pashtoon Murtaza Kasi, et al.. (2018). Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients. Clinical Cancer Research. 24(13). 3014–3025. 72 indexed citations

15.

Pang, Yuan‐Ping, et al.. (2018). Peptide-Binding Groove Contraction Linked to the Lack of T Cell Response: Using Complex Structure and Energy To Identify Neoantigens. ImmunoHorizons. 2(7). 216–225. 7 indexed citations

16.

Lamichhane, Purushottam, Lavakumar Karyampudi, Barath Shreeder, et al.. (2017). IL10 Release upon PD-1 Blockade Sustains Immunosuppression in Ovarian Cancer. Cancer Research. 77(23). 6667–6678. 122 indexed citations

17.

Carlson, Aaron, Matthew J. Maurer, Krista M. Goergen, et al.. (2013). Utility of Progranulin and Serum Leukocyte Protease Inhibitor as Diagnostic and Prognostic Biomarkers in Ovarian Cancer. Cancer Epidemiology Biomarkers & Prevention. 22(10). 1730–1735. 31 indexed citations

18.

Block, Matthew S., Yanice Mendez-Fernandez, Virginia P. Van Keulen, et al.. (2005). Inability of bm14 Mice to Respond to Theiler’s Murine Encephalomyelitis Virus Is Caused by Defective Antigen Presentation, Not Repertoire Selection. The Journal of Immunology. 174(5). 2756–2762. 4 indexed citations

19.

Block, Matthew S., Michael J. Hansen, Virginia P. Van Keulen, & Larry R. Pease. (2003). MHC Class I Gene Conversion Mutations Alter the CD8 T Cell Repertoire. The Journal of Immunology. 171(8). 4006–4010. 8 indexed citations

20.

Block, Matthew S., Aaron J. Johnson, Yanice Mendez-Fernandez, & Larry R. Pease. (2001). Monomeric Class I Molecules Mediate TCR/CD3ε/CD8 Interaction on the Surface of T Cells. The Journal of Immunology. 167(2). 821–826. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact